Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does LENVATINIB Cause Systemic inflammatory response syndrome? 5 Reports in FDA Database

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

According to the FDA Adverse Event Reporting System (FAERS), 5 reports of Systemic inflammatory response syndrome have been filed in association with LENVATINIB (Lenvima). This represents 0.0% of all adverse event reports for LENVATINIB.

5
Reports of Systemic inflammatory response syndrome with LENVATINIB
0.0%
of all LENVATINIB reports
1
Deaths
4
Hospitalizations

How Dangerous Is Systemic inflammatory response syndrome From LENVATINIB?

Of the 5 reports, 1 (20.0%) resulted in death, 4 (80.0%) required hospitalization.

Is Systemic inflammatory response syndrome Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for LENVATINIB. However, 5 reports have been filed with the FAERS database.

What Other Side Effects Does LENVATINIB Cause?

Diarrhoea (4,262) Hypertension (4,152) Fatigue (3,603) Decreased appetite (3,257) Malignant neoplasm progression (2,929) Nausea (2,492) Blood pressure increased (2,228) Vomiting (1,962) Asthenia (1,643) Malaise (1,602)

What Other Drugs Cause Systemic inflammatory response syndrome?

DOXORUBICIN (161) METHOTREXATE (158) CYCLOPHOSPHAMIDE (153) CYTARABINE (153) METHYLPREDNISOLONE (117) ADALIMUMAB (107) RITUXIMAB (106) PREDNISOLONE (99) VINCRISTINE (97) MYCOPHENOLATE MOFETIL (95)

Which LENVATINIB Alternatives Have Lower Systemic inflammatory response syndrome Risk?

LENVATINIB vs LEPONEX LENVATINIB vs LERCANIDIPINE LENVATINIB vs LETAIRIS LENVATINIB vs LETERMOVIR LENVATINIB vs LETROZOLE

Related Pages

LENVATINIB Full Profile All Systemic inflammatory response syndrome Reports All Drugs Causing Systemic inflammatory response syndrome LENVATINIB Demographics